Global Infantile Spasms Therapeutics Market 2016-2018 & 2024

DUBLIN, June 22, 2018 /PRNewswire/ --

The "Infantile Spasms Therapeutics Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.

The report predicts the global infantile spasms therapeutics market to grow with a CAGR of 2.8% over the forecast period of 2018-2024. The report on global infantile spasms therapeutics market provides qualitative and quantitative analysis for the period of 2016 to 2024.

Infantile spasms (IS) is a rare seizure disorder that occurs in young children, usually under one year of age. Infantile spasm refers to sudden stiffening of the body, the arms, and the legs or forward bending of the head. Infantile spasms are caused by an identifiable underlying condition, such as: Central nervous system infections (such as herpes simplex virus, meningitis, and encephalitis), abnormal brain development or injury, Genetic abnormalities and Neurological disorders with skin lesions.

Growing number of births, rising prevalence of infantile spasms and product innovations are factors likely to drive the global infantile spasms therapeutics market. According to the National Organization for Rare Disorders, the incidence of infantile spasms is 2 to 3 per 10,000 live births, with a lifetime prevalence of 1.5 to 2 per 10,000 children. However, stringent regulations for product approvals may hinder the growth of the infantile spasms therapeutics market. Extensive research and development activities, pipeline drugs, and government initiatives are a few more factors projected to fuel the global infantile spasms therapeutics market in the near future.

Geographically, North America is expected to dominate the infantile spasms (IS) market during the forecast period. U.S held the major market share in the North America region owing to innovation of new products, early adoption of treatment procedures and extensive R&D activities. According to a study carried out in U.S around 2K to 4K new cases of infantile spasms disorder occur in the U.S. every year. The Asia pacific region is expected to expand at the highest CAGR during the forecast period owing to rising awareness about this disease and its treatment procedures.

Segments Covered

Global Infantile Spasms Therapeutics Market by Dosage

• Solid
• Liquid

Global Infantile Spasms Therapeutics Market by Route of Administration

• Oral
• Parental

Company Profiles

• Valerion Therapeutics
• Anavex Life Sciences Corp
• Gw Pharmaceuticals
• Mallinckrodt
• H. Lundbeck A/S
• Orphelia Pharma Sa
• Insys Therapeutics Inc.
• Etrophin Inc.
• Catalystpharma

For more information about this report visit https://www.researchandmarkets.com/research/wwr5l5/global_infantile?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets